engleski

Monitoring of Helicobacter pylori eradication by quantitative ELISA Pyloriset EIA-G

Helicobacter pylori (HP) infection results in inflammation of the gastric mucosa, termed chronic superficial gastritis, developing peptic ulceration in some patients. Proper treatment includes eradication of the causative microorganism. The aim of this study was to monitor the efficacy of anti-HP treatment by noninvasive quantitative serologic methods. The concentration of specific anti-HP IgG was measured in serum of 86 patients with positive dyspeptic illness history before treatment, and two, four and six months after the treatment by ELISA Pyloriset EIA-G (Orion Diagnostica, Finland) with a cutoff titer of 300 mg/l. Results showed that the mean percentage of titer decrease was greatest two months after treatment (47%, p<0.001). Statistically significant decrease continued after 4 and 6 months, respectively (58% and 69% of titer before therapy, p<0.05). According to some other authors, it would be satisfying to monitor titer during 4 months to be sure that HP is eradicated. Unlike those studies, our results show that 11% of patients become seroconverted (patients who˘s titer declined ł40 % of the value measured before therapy) not earlier than after 6 months, so we recommend six months monitoring.

Helicobacter pylori; gastritis; monitoring treatment; serology

nije evidentirano